Recent Updates
Recently added Catalysts

Crinetics Pharmaceuticals, Inc.

CRNX
Richly ValuedPharma · Commercial
FDA catalysts, PDUFA dates & pipeline intelligence
$84.95
▲ 0 · 0%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CRNX financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $32.3052W HIGH $85.01
Volume
8.21 M
Value Traded
196.15 M
Short % Float
6.8%
+0.13%Week
+1.13%1 Month
+158.05%3 Month
+122.21%6 Month
+118.4%5 Year
+91.17%All Time

Cash Data

Unlock CRNX cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
9.01 B
EPS (TTM)
-4.73
P/E Ratio
-
Ent. Value
7.80 B
Total Shares
105.45 M
Float Shares
100.71 M
Insiders
4.01%
Institutions
100.27%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every CRNX catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CRNX Catalyst Timeline

Dated clinical, regulatory and corporate events for Crinetics Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Crinetics Pharmaceuticals, Inc.

500Total events
12Upcoming
102Tier-1 (high impact)
2017 to 2026Coverage

Upcoming catalysts 2

TBD
T3Enrollment Update
Subscribe to view catalyst details
atumelnant
TBD
T3Trial Registered
Subscribe to view catalyst details
atumelnant

Event history 50

▲Rare Pediatric DiseaseatumelnantDesignation
FDA grants Rare Pediatric Disease Designation to atumelnant
classic congenital adrenal hyperplasiasource ↗
●Quarterly UpdateCorporate
Q2 2026 financial results reported
source ↗
●Timing GuidancePresentation
Crinetics withdraws financial guidance due to pending acquisition
source ↗
◆AcquisitionCorporate
Vertex to acquire Crinetics for $85.00 per share
source ↗
▲Product LaunchPALSONIFYApprovedPost-Market
PALSONIFY U.S. commercial launch ongoing
acromegalysource ↗
◆Poster PresentationPaltusotineApprovedPresentation
Real-World Biochemical Control in Acromegaly: Insights from US Claims and Laboratory Data
acromegalysource ↗
◆Poster PresentationatumelnantPresentation
Model-Informed Atumelnant Dose Selection for a Phase 3 Study in Adult Patients With Classic Congenital Adrenal Hyperplasia
congenital adrenal hyperplasiasource ↗
◆Oral PresentationatumelnantPresentation
‘Block And Replace’ Atumelnant (CRN04894) And Physiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In ACTH-dependent Cushing Syndrome
ACTH-dependent Cushing's syndromesource ↗
▲Oral PresentationPALSONIFYApprovedPresentation
Oral presentation of up to 2-year OLE data from PATHFNDR-1 and PATHFNDR-2 at ENDO 2026
acromegalysource ↗
◆Oral PresentationPaltusotineApprovedPresentation
Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies
acromegalysource ↗
Unlock the full CRNX catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CRNX actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-14Atumelnant (CRN04894) Phase 2 data readout Phase 2
Unlock 11 more CRNX historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

C51 / 100
Pipeline Score
$1.3B
Pipeline Value
$185M
Commercial Value
Richly Valued
Valuation Signal
6
Drugs Scored
0.2x
rNPV / MCap
Crinetics Pharmaceuticals, Inc. carries a moderate pipeline score (51/100), with $2.1B risk-adjusted pipeline value, led by 68Ga-R10602 in Locoregionally Recurrent Hormone-receptor Positive Breast Cancer (Phase 1).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $42.2M x 4.4 = $185M
ProductRevenuePrior periodChange
PALSONIFY$40M--
Showing 1 of 6 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
68Ga-R10602 Small moleculeCompletedNCT06745804Locoregionally Recurrent Hormone-receptor Positive Breast CancerPhase 1 COMPLETED 27May 4, 2026
Unlock the CRNX pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CRNX program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
atumelnant
OrphanRare Pediatric
Congenital Adrenal Hyperplasia (CAH)Phase 22026-06-14A4 change: -67%; participants achieving normal doses: 88%; participants completed: 8Read MoreCrinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026Read More
Scroll for more · summaries link to the source press release
Unlock every CRNX trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CRNX insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Struthers Richard ScottDirector, Officer (President & CEO)Option 3,969 408,747 held$25.19 08/07/2026
Unlock the full CRNX insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in CRNX

Fund % of Portfolio Current MV Shares Owned Activity
BAKER BROS. ADVISORS 0.4 % (-20 %) 87.99 M 2.35 M
Unlock every fund holding CRNX
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CRNX
Shares held by hedge funds each quarter, and who bought or sold.

CRNX Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CRNX option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CRNX option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CRNX options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CRNX ranks across every disease it competes in

Competitive Position is a premium feature
See how CRNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CRNX News

About Crinetics Pharmaceuticals, Inc.

San Diego, CA 594 employees crinetics.com
Headquarters6055 LUSK BLVD., SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next CRNX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime